Modulators of prostate-specific G-protein receptor (PSGR/OR51E2) and methods of using same
The present disclosure provides, in part, modulators of prostate-specific G-protein receptor (OR51E2/PSGR) and methods of treating, preventing, and diagnosing prostate cancer using the same.
1. A method of treating prostate cancer or preventing the progression of prostate cancer in a subject in need thereof, comprising: administering to the subject a composition consisting of a therapeutically effective amount of one or more OR51E2 ligands and optionally one or more pharmaceutically acceptable carriers, excipients, adjuvants, and diluents, wherein the one or more OR51E2 ligands is 13-cis retinoic acid, or isomers thereof, wherein the one or more ligands binds to OR51E2 on a prostate cancer cell and impedes the progression of the prostate cancer cell, and wherein the prostate cancer cell is a castrate resistant prostate cancer cell.
2. The method of claim 1 , wherein the OR51E2 ligandS is 13-cis retinoic acid.
3. The method of claim 1 , wherein the subject suffers from chronic infection or inflammation.
4. The method of claim 1 , wherein the subject suffers from a P. acnes infection.
5. A method of impeding the progression of a prostate cancer cell, comprising contacting the prostate cancer cell with one or more OR51E2 ligands, wherein the one or more OR51E2 ligands is selected from the group consisting of 13-cis retinoic acid and isomers thereof, and wherein the prostate cancer cell is a castrate resistant prostate cancer cell.
6. The method of claim 5 , wherein the OR51E2 ligands is 13-cis retinoic acid.